Published in Mol Cancer Res on April 01, 2007
A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell (2009) 6.23
A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res (2009) 3.38
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol (2011) 3.33
Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood (2010) 2.61
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res (2012) 2.26
An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. Blood (2011) 2.16
Noxa: at the tip of the balance between life and death. Oncogene (2008) 2.09
Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat Rev Cancer (2009) 2.02
Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nat Rev Cancer (2016) 1.42
BH3 mimetics to improve cancer therapy; mechanisms and examples. Drug Resist Updat (2007) 1.33
Bcl-2 family proteins as regulators of oxidative stress. Semin Cancer Biol (2008) 1.23
The Role of BH3-Only Proteins in Tumor Cell Development, Signaling, and Treatment. Genes Cancer (2011) 1.23
Apoptotic cell signaling in cancer progression and therapy. Integr Biol (Camb) (2011) 1.22
Quantitative model of R-loop forming structures reveals a novel level of RNA-DNA interactome complexity. Nucleic Acids Res (2011) 1.10
Lessons from a decade of integrating cancer copy number alterations with gene expression profiles. Brief Bioinform (2011) 1.08
DNA copy number aberrations in small-cell lung cancer reveal activation of the focal adhesion pathway. Oncogene (2010) 0.99
YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context. Mol Cancer Ther (2013) 0.91
Targeting BCL2-Proteins for the Treatment of Solid Tumours. Adv Med (2014) 0.89
Glucocorticoid receptor over-expression promotes human small cell lung cancer apoptosis in vivo and thereby slows tumor growth. Endocr Relat Cancer (2010) 0.88
Archival fine-needle aspiration cytopathology (FNAC) samples: untapped resource for clinical molecular profiling. J Mol Diagn (2010) 0.87
Genomic analysis and selective small molecule inhibition identifies BCL-X(L) as a critical survival factor in a subset of colorectal cancer. Mol Cancer (2015) 0.82
Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer. Cell Death Dis (2014) 0.81
Novel therapeutic approaches for small cell lung cancer: the future has arrived. Curr Probl Cancer (2012) 0.77
TGF-β/ SMAD3 Pathway Stimulates Sphingosine-1-phosphate Receptor 3 Expression: Implication of Sphingosine-1-Phosphate Receptor 3 in Lung Adenocarcinoma Progression. J Biol Chem (2016) 0.75
An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 22.40
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature (2004) 12.75
Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med (2011) 12.52
ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res (2008) 9.65
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med (2013) 8.89
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09
Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res (2002) 5.99
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol (2002) 5.20
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet (2007) 5.19
Frequent EpCam protein expression in human carcinomas. Hum Pathol (2004) 4.94
Conversion of mouse fibroblasts into cardiomyocytes using a direct reprogramming strategy. Nat Cell Biol (2011) 4.64
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A (2008) 4.57
Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol (2004) 4.43
Productivity is a poor predictor of plant species richness. Science (2011) 4.21
Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell (2010) 4.16
Valley-selective circular dichroism of monolayer molybdenum disulphide. Nat Commun (2012) 4.04
Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol (2007) 4.02
Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol Cell (2011) 3.78
HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol (2009) 3.37
Generation of functional human hepatic endoderm from human induced pluripotent stem cells. Hepatology (2010) 3.36
Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet (2002) 3.32
Structural and electronic properties of T graphene: a two-dimensional carbon allotrope with tetrarings. Phys Rev Lett (2012) 3.30
Virtual autopsy as an alternative to traditional medical autopsy in the intensive care unit: a prospective cohort study. Ann Intern Med (2012) 3.29
Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res (2007) 3.24
siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res (2005) 3.21
Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell (2013) 3.08
Adult mouse epicardium modulates myocardial injury by secreting paracrine factors. J Clin Invest (2011) 2.99
Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat Med (2006) 2.94
Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res (2005) 2.85
Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol (2011) 2.78
Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. Eur Urol (2009) 2.76
Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy series. Eur Urol (2008) 2.72
Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene (2003) 2.71
Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res (2004) 2.55
A novel regulator of macrophage activation: miR-223 in obesity-associated adipose tissue inflammation. Circulation (2012) 2.55
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol (2010) 2.48
POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res (2003) 2.45
Super plastic bulk metallic glasses at room temperature. Science (2007) 2.45
Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet (2004) 2.44
Direct conversion of fibroblasts to neurons by reprogramming PTB-regulated microRNA circuits. Cell (2013) 2.43
Marked gene transcript level alterations occur early during radical prostatectomy. Eur Urol (2007) 2.41
Prevalence of KIT expression in human tumors. J Clin Oncol (2004) 2.40
Transcription control by E1A and MAP kinase pathway via Sur2 mediator subunit. Science (2002) 2.33
Expression and prognostic relevance of annexin A3 in prostate cancer. Eur Urol (2008) 2.32
Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am J Pathol (2004) 2.32
Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res (2005) 2.31
An adenosine nucleoside inhibitor of dengue virus. Proc Natl Acad Sci U S A (2009) 2.20
High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat (2004) 2.14
The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat (2005) 2.10
Cloning of BCAS3 (17q23) and BCAS4 (20q13) genes that undergo amplification, overexpression, and fusion in breast cancer. Genes Chromosomes Cancer (2002) 2.04
Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol (2004) 2.04
Ivabradine significantly improves cardiac function in patients with ischemic heart disease: a meta-analysis of randomized controlled trials. Int J Cardiol (2013) 1.96
Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther (2002) 1.96
Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol (2004) 1.95
Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78. Cancer Res (2005) 1.94
Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest (2008) 1.91
Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J Med Chem (2008) 1.85
Herpes simplex virus 1-infected cell protein 0 contains two E3 ubiquitin ligase sites specific for different E2 ubiquitin-conjugating enzymes. Proc Natl Acad Sci U S A (2002) 1.82
Alpha-enolase as a potential cancer prognostic marker promotes cell growth, migration, and invasion in glioma. Mol Cancer (2014) 1.81
DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumor growth. Mol Cell Biol (2006) 1.80
Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol (2012) 1.80
Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir. Nat Struct Mol Biol (2004) 1.78
Control of bone formation by the serpentine receptor Frizzled-9. J Cell Biol (2011) 1.77
ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res (2011) 1.75
Generation of a mouse model of Von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1α. Cancer Res (2011) 1.75
Influence of slide aging on results of translational research studies using immunohistochemistry. Mod Pathol (2004) 1.75
High incidence of EMMPRIN expression in human tumors. Int J Cancer (2006) 1.74
Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res (2004) 1.74
mir-17-92 cluster is required for and sufficient to induce cardiomyocyte proliferation in postnatal and adult hearts. Circ Res (2013) 1.72
Arterial neovascularization and inflammation in vulnerable patients: early and late signs of symptomatic atherosclerosis. Circulation (2004) 1.68
A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res (2006) 1.67
PRC2 directly methylates GATA4 and represses its transcriptional activity. Genes Dev (2012) 1.66
SOX4 expression in bladder carcinoma: clinical aspects and in vitro functional characterization. Cancer Res (2006) 1.66
Cytoplasmic and nuclear retained DMPK mRNAs are targets for RNA interference in myotonic dystrophy cells. J Biol Chem (2005) 1.64
AMACR expression in colorectal cancer is associated with left-sided tumor localization. Virchows Arch (2008) 1.61
Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR. J Pathol (2002) 1.59
Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol (2006) 1.56
Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int J Cancer (2005) 1.55
NMDA receptor activation increases free radical production through nitric oxide and NOX2. J Neurosci (2009) 1.54
Impaired gastric acidification negatively affects calcium homeostasis and bone mass. Nat Med (2009) 1.52
ER stress in the brain subfornical organ mediates angiotensin-dependent hypertension. J Clin Invest (2012) 1.51
Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol (2008) 1.51
Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res (2003) 1.51
Tumor volume in insignificant prostate cancer: increasing threshold gains increasing risk. Prostate (2014) 1.50
Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res (2005) 1.49
Protective effects of tranexamic acid on clopidogrel before coronary artery bypass grafting: a multicenter randomized trial. JAMA Surg (2013) 1.49
Secondhand Smoking Is Associated With Vascular Inflammation. Chest (2015) 1.48
VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol (2002) 1.48
Epimorphic regeneration approach to tissue replacement in adult mammals. Proc Natl Acad Sci U S A (2009) 1.47
The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother Pharmacol (2010) 1.47
Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs (2003) 1.47
Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational study. World J Biol Psychiatry (2009) 1.46
Efficacy and safety of tadalafil monotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a meta-analysis. Urol Int (2013) 1.46
Tbx20 regulates a genetic program essential to adult mouse cardiomyocyte function. J Clin Invest (2011) 1.46
Activation of HIF2α in kidney proximal tubule cells causes abnormal glycogen deposition but not tumorigenesis. Cancer Res (2013) 1.46